The Herpes Simplex virus is presently treated with Acyclovir. Many strains are developing resistance to this drug. Extracellular Polysaccharides (EPS) from marine organisms are now being increasingly found to be effective against a variety of viruses, particularly HSV. The present marine microbial source from Myko Tech is novel and a patent has been filed.
Summary of work carried out so far: A 100 % neutralization of the cytopathic effect caused by Herpes Simplex Virus Type-1 in animal cell lines has been achieved using just about 20 μg per ml of the EPS. No cytotoxic effects were noticed at this dosage. The effects were comparable to Acyclovir and the EPS is expected to be active even against Acyclovir-resistant strains of HSV.
Contact person : Dr Raghukumar (9098904 50007),Goa, India